POMNasdaqRetail-Miscellaneous RetailFiscal year ends December 31
POMDOCTOR Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 14, 2026
$0.53−0.10 (-15.88%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
13.1%
Operating margin
-29.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.7% | – | – | – | |
| Gross profit | +9.6% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 0.48 | |
| Interest coverage | – | – | -30.1× | |
| Capex to revenue | – | – | 0.3% | |
| Diluted shares | – | – | 10M |
Cash use needs five years of cash flow figures
Pomdoctor does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CN¥148.48M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CN¥148.48M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.21 → 0.48
- No dilutionShare count did not rise6M → 10M
- Gross margin improvedGross margin up on the prior year13.92% → 13.07%
- More efficientAsset turnover rose– → 8.65